ASN: Levofloxacin Doesn't Halt Post-Transplant BK Viruria

This article originally appeared here.
Share this content:
ASN: Levofloxacin Doesn't Halt Post-Transplant BK Viruria
ASN: Levofloxacin Doesn't Halt Post-Transplant BK Viruria

TUESDAY, Nov. 18, 2014 (HealthDay News) -- A three-month course of levofloxacin does not prevent BK viral reactivation in the urine (BK viruria) in kidney transplant recipients, according to a study published online Nov. 15 in the Journal of the American Medical Association. The research was published to coincide with the American Society of Nephrology's Kidney Week 2014, held from Nov. 11 to 16 in Philadelphia.

Greg A. Knoll, M.D., from the University of Ottawa in Canada, and colleagues examined whether levofloxacin can prevent BK viruria in kidney transplant recipients in a placebo-controlled randomized trial. One hundred fifty-four patients who received a living or deceased donor kidney-only transplant were randomized to receive a three-month course of levofloxacin (76 patients) or placebo (78 patients).

The researchers found that BK viruria occurred in 29 percent of the levofloxacin group and 33.3 percent in the placebo group (hazard ratio, 0.91; P = 0.58). There was no significant between-group difference with respect to any secondary end points. In the levofloxacin versus placebo group there was an increased risk of resistant infection among isolates usually sensitive to quinolones (58.3 versus 33.3 percent; risk ratio, 1.75; 95 percent confidence interval, 1.01 to 2.98) and a nonsignificantly increased risk of suspected tendonitis (7.9 versus 1.3 percent; risk ratio, 6.16; 95 percent confidence interval, 0.76 to 49.95).

"These findings do not support the use of levofloxacin to prevent post-transplant BK virus infection," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »